| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 3740.2 | 3603.3 | 3371.1 |
| Other income | 152.8 | 200.1 | 136.5 |
| Total income | 3892.9 | 3803.4 | 3507.6 |
| Profit before exceptional items & tax | 772.0 | 557.8 | 758.1 |
| Exceptional items | 0.0 | -135.0 | 12.9 |
| Profit before tax | 772.0 | 422.9 | 771.0 |
| Net profit | 521.0 | 251.1 | 667.9 |
| Operating margin | 19.8% | 11.1% | 22.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -22.00% |
|---|---|
| Net profit, quarter on quarter | +107.50% |
| Revenue, year on year | +10.90% |
| Operating profit, year on year | -0.40% |
| Operating profit, quarter on quarter | +73.10% |
NSE results filing, NSE: ALKEM. Figures extracted from the filing.
Alkem Laboratories Ltd: key numbers
- Share price
- ₹5,350.50
- Market cap
- ₹63,973 Cr
- Revenue (annual)
- ₹14,712 Cr
- Net profit (annual)
- ₹2,302 Cr
- P/E (TTM)
- 29.6×Sector 47.3×
- Promoter holding
- 49.70%-1.50% QoQ
- FII holding
- 10.42%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alkem Laboratories Ltd
All →Alkem Laboratories Management Change
Alkem Laboratories CFO Nitin Agrawal resigned effective 30 September 2026 for new opportunities. He was also a Key Managerial Personnel of the company.
Alkem Laboratories Debt & Borrowing: ₹593.5 Cr
Alkem Laboratories issued a Corporate Guarantee of Euro 54.45 Million to HSBC UK Bank for a Euro 49.5 Million term loan taken by its subsidiary, Occlutech Holding.
- Value
- ₹593.5 Cr
Alkem Laboratories Product Launch
Alkem launches NeuCeno (cenobamate), an anti-seizure medication for partial-onset seizures in adults, for the first time in India. The once-daily drug is available in six tablet strengths.
Alkem Laboratories Management Change
Alkem Laboratories has appointed Dr. Shubhadeep Sinha as a Senior Management Personnel, effective September 15, 2026. This appointment falls under standard senior management disclosures.
Alkem Laboratories Product Launch
Alkem launched Renocia Exo, a patented exosome-based hair growth serum. It expands the company's dermatology portfolio with a new follicle-support therapy.
Alkem Laboratories Annual General Meeting
Alkem Laboratories Limited concluded its 52nd Annual General Meeting on August 27, 2026. All resolutions proposed in the notice were duly approved by the members.